22 Dec Ion Beam Applications
Ion Beam Applications (IBA) is the market leader in advanced cancer radiation therapy technologies. The company’s expertise lies in the development of innovative proton therapy technologies for cancer patients and suppling the oncological world with world class equipment. IBA’s therapy leads to a 50% to 80% lower risk of causing secondary cancer compared to traditional x-rays therapy. Cancer is among the leading causes of mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades. The company is listed on the NYSE Euronext Brussels.
IBA has completed 50,000 treatments as of 2016 and the number of new treatments is expected to double by 2020
In 2015, IBA launched a new program to improve its energy consumption and reduce the ecological impact of its industrial processes
Net income growth was 151.9% in 2015
The EBITDA margin was 24.5% in 2015